Clinical trial NCT06200571: Biological Changes Associated with High Risk of Preeclampsia in Nulliparous Women
Official title: Characterization of the Immunological and Vascular Effects of Aspirin in Prevention of Preeclampsia in High-risk Nulliparous Women
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Preeclampsia
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: Alesund Hospital
name: St. Olavs Hospital
First posted: 2024-01-11
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Nulliparous women with low and high risk for preeclampsia, defined by FMF-screening in week 11-14 of pregnancy

Brief summary: Primary outcome

1. to identify biological changes in nulliparous women at high risk for preeclampsia defined by combined screening by Fetal Medicine Foundation (FMF)
2. to identify biological effects of aspirin in nulliparous women with high risk for preeclampsia

Secondary outcomes include findings of longitudinal development and predictive potential of biological markers associated with high-risk for preeclampsia and aspirin treatment.

The main questions it aims to answer are:

* Is high risk for preeclampsia associated with biological changes during pregnancy?
* How does aspirin modulate the biological changes associated with high risk for preeclampsia?

Nulliparous women will undergo routine clinical care at two regional hospitals with different treatment strategies, and selected to the study in three groups: low risk of preeclampsia, high risk of preeclampsia without aspirin, and high-risk of preeclampsia with aspirin treatment.

Detailed description: St. Olavs Hospital offers FMF-screening in week 11-14 and aspirin treatment through the "Implementing Screening for Preeclampsia in Norway With Aspirin Discontinuation at 24-28 Weeks - a Randomized Controlled Trial" (NCT06108947). FMF-screening and aspirin treatment are not part of routine clinical care at Alesund Hospital according to current recommendations from the Norwegian health authorities. Alesund Hospital will therefore perform FMF-screening only to determine the project specific study groups. Researchers will compare the three groups to identify biological changes associated with high risk for preeclampsia and the effect of aspirin.

FMF- screening will be performed in week 11-14 after written, informed consent (approved by the the Regional Committee for Medical and Health Research Ethics in Central Norway (REK-midt), REK 537602). Screening includes patient history, blood pressure, uterine artery mean pulsatile index and serum placenta growth factor (PlGF). Standardized blood pressure will be measured by trained personnel. Ultrasound scans will be performed by FMF certified doctors and midwives working at Alesund Hospital and the Center for Fetal Medicine at St.Olavs Hospital in Trondheim. PlGF in maternal serum will be analyzed with Roche or Kryptor technology.

The investigators will include around 200 women, 18 years or older, with a singleton live fetus, in three groups:

* Nulliparous women with low risk for preeclampsia (at both hospitals)
* Nulliparous women with high risk for preeclampsia without aspirin (at Alesund Hospital)
* Nulliparous women with high risk for preeclampsia with aspirin (at St. Olavs Hospital)

Follow-up: all three groups will have visits in week 22-24, 32 and 38, and standard antenatal care after 37 weeks until delivery. Fetal growth and Doppler will be assessed at the scheduled visits and according to clinical judgement by obstetricians at the outpatient clinic of the hospital. Women will have follow-up 6 months after birth.

Blood and urine will be sampled at five time points for all three groups (week 11-14, 22-24, 32, 38 and 6 months after birth) for biological analyses. Placenta samples and umbilical venous blood will be sampled at delivery.

Biological materials will be investigated to answer the research questions described. Biological changes in serum will be measured as cytokines by multiplex, metabolites by NMR-analysis, and lipids by NMR-analysis. Vascular changes in the placenta will be measured by histopathological evaluation.

The study will be registered in Clinicaltrials.gov

Funding and sponsors: The study is funded by Helse-Midt Norge RHF. The funding source has played no role in design of the study and will have no role in data collection, analyses, interpretation or publication.

Participants: Ann-Charlotte Iversen, professor, Phd, Project leader Åse Turid Rossevatn Svoren, consultant, MD, Phd candidate, Kjell Åsmund Salvesen, professor, MD, PhD, Solveig Bjellmo, consultant, MD, Phd

Eligibility criteria: Inclusion Criteria:

* 18 years or older
* nulliparous women
* singleton live fetus
* FMF risk \> 1/100 (high risk), or \< 1/150 (low risk)

Exclusion Criteria:

* not speaking Norwegian or English language
* fetal anomalies diagnosed with ultrasound

Primary outcomes:
measure: Maternal serum cytokine profile in week 11-13, 22-24, 32 and 38 and 6 months post partum
timeFrame: December 2028
measure: Maternal serum cytokine profile in week 11-13, 22-24, 32 and 38 and 6 months post partum
timeFrame: December 2028
Secondary outcomes:
measure: Maternal serum metabolite profile in week 11-13, 22-24, 32 and 38 and 6 months post partum
timeFrame: December 2028
measure: Maternal serum lipid profile in week 11-13, 22-24, 32 and 38 and 6 months post partum
timeFrame: December 2028
measure: Maternal serum metabolite profile in week 11-13, 22-24, 32 and 38 and 6 months post partum
timeFrame: December 2028
measure: Maternal serum lipid profile in week 11-13, 22-24, 32 and 38 and 6 months post partum
timeFrame: December 2028
measure: Maternal vascular malperfusion in the placenta
timeFrame: December 2028
measure: Fetal vascular malperfusion in the placenta
timeFrame: December 2028
measure: Maternal vascular malperfusion in the placenta
timeFrame: December 2028
measure: Fetal vascular malperfusion in the placenta
timeFrame: December 2028
measure: Fetal cord serum cytokine profile
timeFrame: December 2028
measure: Fetal cord serum metabolite profile
timeFrame: December 2028
measure: Fetal cord serum lipid profile
timeFrame: December 2028
measure: Fetal cord serum cytokine profile
timeFrame: December 2028
measure: Fetal cord serum metabolite profile
timeFrame: December 2028
measure: Fetal cord serum lipid profile
timeFrame: December 2028
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: St. Olavs Hospital
city: Ålesund
country: Norway
facility: Alesund Hospital
Study officials:
affiliation: Norwegian University of Science and Technology
name: Ann-Charlotte Iversen, Professor
role: STUDY_DIRECTOR
References: